Data CitationsThomas E, Sarah EH, Alexandra CV, Nir H
Data CitationsThomas E, Sarah EH, Alexandra CV, Nir H. continued to be elusive. Its constitutive expression on resting and activated T cells precludes it from being a exhaustion marker. By breeding Pmel-1 mice with SLAMF6 -/- mice, we generated donors for T cells lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 -/- CD8+ T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant transcription factor in Pmel-1 x SLAMF6 -/- cells, and upon activation, they acquired an effector-memory phenotype. Adoptive transfer of Pmel-1 x SLAMF6 -/- T cells to melanoma-bearing mice resulted in lasting tumor regression in contrast to temporary responses achieved with Pmel-1 T cells. LAG-3 expression was elevated in the SLAMF6 -/- cells, and the addition of the LAG-3-blocking antibody to the adoptive transfer protocol improved the SLAMF6 -/- T cells and expedited the antitumor response even further. The results from this study support the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8+ T cells to eradicate tumors. gene was knocked out. In this report, we show for SNS-032 ic50 the first time that SLAMF6 -/-?CD8+ T cells display improved anti-melanoma activity and prevent melanoma growth more effectively than CD8+ T cells SNS-032 ic50 with intact and functional SLAMF6. Since SLAMF6 is usually constitutively expressed on T cells, it acts as an inhibitory checkpoint receptor whose absence allows the eradication of established tumors by CD8+ T cells. Results SLAMF6 is usually constitutively expressed on T cells and increases upon activation SLAMF6 is an immune receptor constitutively expressed on non-activated and activated T cells (Eisenberg et al., 2018). The level of SLAMF6 transcription and receptor expression, however, is dynamic, changing with time and activation says. To record SLAMF6 expression in a longitudinal manner, human tumor-infiltrating lymphocytes (TILs) were activated for 5 days, and SLAMF6 transcript and protein expression were measured (Physique 1ACC). After 1 day of activation, there was an initial decrease in the SLAMF6 transcript that switched to over-expression (Physique 1C). From 3 days after activation onward, SLAMF6 receptor expression consistently increased (Physique 1A and B). Interestingly, the increased expression was most pronounced in T cells activated in the absence of IL-2 (Physique 1D). A similar pattern was observed for the expression of the murine SLAMF6 receptor on Pmel-1 CD8+ T cells (Physique 1E). Open in a separate window Physique 1. SLAMF6 is usually constitutively ARF6 expressed on T cells and increases upon activation.(ACC) SLAMF6 expression in human TIL412 cells, activated for five days. (A) Flow cytometry at the indicated time points. (B) Median fluorescence intensity (MFI) of SLAMF6, days 1C5. (C) Quantitative RT-PCR for expression at each time point and to the basal expression level on day 0. One-way ANOVA. **, p 0.01, ***, p 0.001. (D) SLAMF6 expression by flow cytometry in human TIL412 cells activated for 5 days with anti-CD3 or with anti-CD3 plus IL-2, at the indicated time points.?(E) SLAMF6 expression by flow cytometry in Pmel-1 mouse splenocytes activated for 6 days, at the indicated time points.?(F) Row normalized expression of immune-related genes from RNAseq, clustered according to comparable expression patterns. CD4+ T cells from two donors were stimulated with anti-CD3 SNS-032 ic50 plus anti-CD28 for 72 hr, RNA was extracted and sequenced. Numbers in the top panel indicate hours. (G) Magnification of cluster C. is usually marked. Physique 1source data 1.RNA sequencing of healthy donors CD4 T cells along activation.Click here to view.(70K, csv) To identify other immune-related genes that may cluster with SLAMF6, longitudinal RNA sequencing data were generated from CD4 T cells from two healthy human donors. Five groups of genes (clusters A-E) were identified (Physique 1F). Cluster A represents genes highly expressed in non-activated cells, and downregulated upon activation, such as and transcript appears in cluster C, increasing at 6 hr of activation and keeping SNS-032 ic50 high from then on (Body.